PAREXEL International Corp. (PRXL) Announces Quarterly Earnings Results, Hits Estimates
PAREXEL International Corp. (NASDAQ:PRXL) released its earnings data on Wednesday. The company reported $0.45 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.45, AnalystRatings.NET reports. The company had revenue of $449.20 million for the quarter, compared to the consensus estimate of $458.94 million. During the same quarter in the previous year, the company posted $0.29 earnings per share. The company’s revenue for the quarter was up 13.8% on a year-over-year basis.
PAREXEL International Corp. (NASDAQ:PRXL) opened at 54.85 on Wednesday. PAREXEL International Corp. has a 52-week low of $27.50 and a 52-week high of $53.55. The stock’s 50-day moving average is $48.71 and its 200-day moving average is $44.69. The company has a market cap of $3.084 billion and a P/E ratio of 33.82.
PRXL has been the subject of a number of recent research reports. Analysts at Robert W. Baird downgraded shares of PAREXEL International Corp. from an “outperform” rating to a “neutral” rating in a research note to investors on Friday, October 25th. They noted that the move was a valuation call. On a related note, analysts at Sterne Agee reiterated an “underperform” rating on shares of PAREXEL International Corp. in a research note to investors on Monday, October 7th. They now have a $51.07 price target on the stock, up previously from $36.00. Finally, analysts at ISI Group upgraded shares of PAREXEL International Corp. from a “neutral” rating to a “buy” rating in a research note to investors on Friday, October 4th. They now have a $57.00 price target on the stock, up previously from $52.50. One research analyst has rated the stock with a sell rating, six have given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. PAREXEL International Corp. presently has an average rating of “Hold” and an average price target of $49.88.
PAREXEL International Corporation (NASDAQ:PRXL) is a biopharmaceutical services company, providing a range of expertise in clinical research, medical communications, consulting, and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.